[Percutaneous closure of patent foramen ovale: a wise approach]

Achille Gaspardone1, Cesare Iani, Marco Papa

  • 1U.O.C. di Cardiologia, Ospedale S. Eugenio, ASL Rm C, Roma. a_gaspardone@yahoo.com

Giornale Italiano Di Cardiologia (2006)
|September 12, 2008
PubMed

Insights

Patent foramen ovale (PFO) closure may not be effective for preventing cryptogenic stroke or treating migraines. Current evidence is insufficient, and the procedure carries risks, necessitating a cautious approach for patients.

Area of Science:

  • Cardiology and Neurology
  • Medical Device Technology
  • Clinical Trial Analysis

Context:

  • Patent foramen ovale (PFO) is a common remnant of fetal circulation.
  • PFO is associated with cryptogenic stroke, migraine, and other conditions.
  • Transcatheter closure is an alternative to medical therapy for PFO-related issues.

Purpose:

  • To evaluate the efficacy of transcatheter PFO closure for cryptogenic stroke and migraine.
  • To review current evidence from observational studies and randomized trials.
  • To assess the risks versus benefits of PFO closure procedures.

Summary:

  • Observational studies suggest PFO closure may reduce stroke recurrence and improve migraine symptoms.
  • Randomized trials, like the MIST trial, have not confirmed these benefits for migraine.
  • Evidence for PFO closure in preventing cryptogenic stroke recurrence is also insufficient.

Impact:

  • Transcatheter PFO closure is not currently recommended for stroke prevention or migraine therapy due to insufficient evidence.
  • The procedure has associated risks (1.5-2% major complications).
  • A prudent, individualized approach is essential when considering PFO closure.